Marshall Wace
CERE

Marshall Wace’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Marshall Wace’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,869,340
Closed -$76.4M – 3075
2024
Q2 		$76.4M Buy
1,869,340
+647,074
+53% +$26.9M 0.1% 189
2024
Q1 		$51.7M Buy
1,222,266
+909,304
+291% +$38.2M 0.08% 247
2023
Q4 		$13.3M Buy
+312,962
New +$8.99M 0.02% 601
2021
Q2 		– Sell
-23,597
Closed -$324K – 3212
2021
Q1 		$324K Sell
23,597
-44,175
-65% -$646K ﹤0.01% 2105
2020
Q4 		$1.12M Buy
+67,772
New +$880K 0.01% 1164

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Marshall Wace's CERE Position: Q3 2024 in Review

Marshall Wace sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 1,869,340 shares — an estimated $76.4M sold.

Marshall Wace first reported a position in CERE in Q4 2020 and held it in 5 quarters. The position peaked at $76.4M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Marshall Wace reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Marshall Wace sold 1,869,340 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $76.4M.
  • Marshall Wace first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
  • Marshall Wace's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $76.4M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Marshall Wace's 13F filing for Q3 2024, filed 14 Nov 2024.